Homatropine

Homatropine
Clinical data
AHFS/Drugs.com	Monograph
MedlinePlus	a601006
ATC code	S01FA05 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name (N-Methyl-8-azabicyclo[3.2.1]oct-3-yl) 2-hydroxy-2-phenylacetate;
CAS Number	87-00-3 ;
PubChem CID	6321423;
DrugBank	DB00725 ;
ChemSpider	16498795 ;
UNII	8QS6WCL55Z;
ChEMBL	ChEMBL1233442 ;
CompTox Dashboard (EPA)	DTXSID6044014 ;
ECHA InfoCard	100.001.561
Chemical and physical data
Formula	C16H21NO3
Molar mass	275.348 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN3[C@H]1CC[C@@H]3C[C@@H](C1)OC(=O)C(O)c2ccccc2;
	InChI InChI=1S/C16H21NO3/c1-17-12-7-8-13(17)10-14(9-12)20-16(19)15(18)11-5-3-2-4-6-11/h2-6,12-15,18H,7-10H2,1H3/t12-,13 ,14 ,15? ; Key:ZTVIKZXZYLEVOL-MCOXGKPRSA-N ;
	(what is this?) (verify)

Homatropine (Equipin, Isopto Homatropine) is an anticholinergic medication that is an antagonist at muscarinic acetylcholine receptors and thus the parasympathetic nervous system. It is used in eye drops as a cycloplegic (to temporarily paralyze accommodation), and as a mydriatic (to dilate the pupil).

The related chemical compound homatropine methylbromide (methylhomatropine) is a different medication. Homatropine is less potent than atropine and has a shorter duration of action. It is available as the hydrobromide salt. Homatropine is also given as an atropine substitute,^[1] given to reverse the muscarinic and CNS effects associated with indirect cholinomimetic (anti-AChase) administration.

Homatropine hydrobromide is on the World Health Organization's List of Essential Medicines.^[2]

It is an antagonist of all five muscarinic acetylcholine receptors.^[3]

Side effects

Blurred vision
Sensitivity to light

Contraindications

References

^ Scharer LL, Burhenne HJ (April 1964). "Megacolon associated with administration of an anticholinergic drug in a patient with ulcerative colitis". The American Journal of Digestive Diseases. 9 (4): 268–274. doi:10.1007/bf02232133. PMID 14142388. S2CID 19169565.
^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
^ Lavrador M, Cabral AC, Veríssimo MT, Fernandez-Llimos F, Figueiredo IV, Castel-Branco MM (January 2023). "A Universal Pharmacological-Based List of Drugs with Anticholinergic Activity". Pharmaceutics. 15 (1): 230. doi:10.3390/pharmaceutics15010230. PMC 9863833. PMID 36678858.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

[1] Scharer LL, Burhenne HJ (April 1964). "Megacolon associated with administration of an anticholinergic drug in a patient with ulcerative colitis". The American Journal of Digestive Diseases. 9 (4): 268–274. doi:10.1007/bf02232133. PMID 14142388. S2CID 19169565.

[WHO23rd-2] World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

[LavradorCabralVeríssimo2023-3] Lavrador M, Cabral AC, Veríssimo MT, Fernandez-Llimos F, Figueiredo IV, Castel-Branco MM (January 2023). "A Universal Pharmacological-Based List of Drugs with Anticholinergic Activity". Pharmaceutics. 15 (1): 230. doi:10.3390/pharmaceutics15010230. PMC 9863833. PMID 36678858.

[1]

[2]

[3]